Feb 2 (Reuters) - NRX Pharmaceuticals Inc :
* NRX PHARMACEUTICALS REPORTS RECOMMENDATIONS OF DATA SAFETY MONITORING BOARD FOR TRIAL OF NRX-101 IN PATIENTS WITH SEVERE BIPOLAR DEPRESSION AND SUBACUTE SUICIDAL IDEATION OR BEHAVIOR
* NRX PHARMACEUTICALS INC-INDEPENDENT DATA SAFETY MONITORING BOARD IDENTIFIED NO SAFETY CONCERNS, ISSUED A RECOMMENDATION TO CONTINUE TRIAL ENROLLMENT
* NRX PHARMACEUTICALS INC - NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS WITH FIRST 50 ENROLLED CLINICAL TRIAL PARTICIPANTS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.